R97.21 Rising PSA following treatment for malignant neoplasm of prostate

Billable ICD-10-CM code, FY2026.

Applies from R97 Abnormal tumor markers

Applicable to

• Elevated tumor associated antigens [TAA]
• Elevated tumor specific antigens [TSA]

MS-DRG index

Defines the logic of DRG(s) 947-948 in MDC 23.

Approximate ICD-9-CM (GEMs)

• 790.93 Elevated prostate specific antigen [PSA] (approximate)

Medicare Code Edits (MCE v43.1 (April 2026))

• Adult diagnoses (age 15 through 124): Age conflict edit. These diagnoses are clinically expected only in patients age 15 through 124.
• Questionable admission: Some diagnoses are not usually sufficient justification for admission to an acute care hospital when reported as principal diagnosis.

Code annotations containing back-references to R97.21

Back-references to R97.21

• Use Additional: C61 Malignant neoplasm of prostate ("rising PSA following treatment for malignant neoplasm of prostate (R97.21)")

Diagnosis Index entries for R97.21

• Rising, PSA following treatment for malignant neoplasm of prostate

Nearby codes

• R97 Abnormal tumor markers
• R97.0 Elevated carcinoembryonic antigen [CEA]
• R97.1 Elevated cancer antigen 125 [CA 125]
• R97.2 Elevated prostate specific antigen [PSA]
• R97.20 Elevated prostate specific antigen [PSA]
• R97.21 Rising PSA following treatment for malignant neoplasm of prostate (this code)
• R97.8 Other abnormal tumor markers